6种死亡风险评分对住院共病老年人1年死亡风险预测的比较
该研究基于OPERAM试验数据,前瞻性比较6种评分(Burden of Illness Score for Elderly Persons、CARING标准、Charlson共病指数、Gagné指数、Levine指数、Walter指数)对住院共病老年人1年全因死亡的预测效能。纳入1879例年龄≥70岁、≥3种慢性病、≥5种长期用药的住院患者,中位年龄79岁,中位慢性病数11种,1年内375例(20.0%)死亡。Brier评分0.16(Gagné指数)至0.24(Burden of Illness Score for Elderly Persons),C统计量0.62(95%CI 0.59-0.65,Charlson共病指数)至0.69(95%CI 0.66-0.72,Walter指数)。Gagné指数校准良好,其余评分校准中等;总体无一种评分优于其他,均不能推荐用于日常临床实践。
要点
- 住院共病老年人(≥70岁、≥3种慢性病、≥5种长期用药)1年全因死亡率为20.0%(375/1879)。
- 6种评分判别力均为中等:C统计量从0.62(95%CI 0.59-0.65,Charlson共病指数)到0.69(95%CI 0.66-0.72,Walter指数)。
- 整体效能Brier评分从0.16(Gagné指数)到0.24(Burden of Illness Score for Elderly Persons)。
- 校准方面Gagné指数良好,其他死亡风险评分中等。
- 作者结论:无一种评分优于其他,均不能推荐用于日常临床实践。
适用人群与场景
- OPERAM试验纳入的住院共病老年人:≥3种共存慢性病、年龄≥70岁、多重用药(≥5种长期用药)、入住参与病房者。
- 场景为比利时鲁汶、荷兰乌得勒支、爱尔兰共和国科克、瑞士伯尔尼4所大学附属医院的外科和非外科病房。
研究设计与关键结果
- 研究类型:前瞻性预后研究,分析OPERAM试验(2016年12月1日至2018年10月31日)参与者数据,数据于2020年4月1日至9月30日分析。
- 样本量1879例,中位(IQR)年龄79(74-84)岁,女性835例(44.4%),中位(IQR)慢性病数11(8-16)种。
- 主要终点:纳入OPERAM试验后第1年内任何原因死亡;1年内375例(20.0%)死亡。
- Brier评分从0.16(Gagné指数)到0.24(Burden of Illness Score for Elderly Persons)。
- C统计量从0.62(95%CI 0.59-0.65,Charlson共病指数)到0.69(95%CI 0.66-0.72,Walter指数)。
- 校准:Gagné指数良好,其他死亡风险评分中等。
- 作者结论:所有6种1年死亡风险评分在大样本住院共病老年人中预后效能、判别力和校准均为中等,总体无一种评分优于其他,均不能推荐用于日常临床实践。
证据类型、等级与局限
- 证据类型:前瞻性预后研究(分析OPERAM试验数据)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为:所有6种1年死亡风险评分预后效能、判别力和校准均为中等,无一种优于其他,均不能推荐用于日常临床实践。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The most appropriate therapy for older adults with multimorbidity may depend on life expectancy (ie, mortality risk), and several scores have been developed to predict 1-year mortality risk. However, often, these mortality risk scores have not been externally validated in large sample sizes, and a head-to-head comparison in a prospective contemporary cohort is lacking.
OBJECTIVE: To prospectively compare the performance of 6 scores in predicting the 1-year mortality risk in hospitalized older adults with multimorbidity.
DESIGN, SETTING, AND PARTICIPANTS: This prognostic study analyzed data of participants in the OPERAM (Optimising Therapy to Prevent Avoidable Hospital Admissions in Multimorbid Older People) trial, which was conducted between December 1, 2016, and October 31, 2018, in surgical and nonsurgical departments of 4 university-based hospitals in Louvain, Belgium; Utrecht, the Netherlands; Cork, Republic of Ireland; and Bern, Switzerland. Eligible participants in the OPERAM trial had multimorbidity (≥3 coexisting chronic diseases), were aged 70 years or older, had polypharmacy (≥5 long-term medications), and were admitted to a participating ward. Data were analyzed from April 1 to September 30, 2020.
MAIN OUTCOMES AND MEASURES: The outcome of interest was any-cause death occurring in the first year of inclusion in the OPERAM trial. Overall performance, discrimination, and calibration of the following 6 scores were assessed: Burden of Illness Score for Elderly Persons, CARING (Cancer, Admissions ≥2, Residence in a nursing home, Intensive care unit admit with multiorgan failure, ≥2 Noncancer hospice guidelines) Criteria, Charlson Comorbidity Index, Gagné Index, Levine Index, and Walter Index. These scores were assessed using the following measures: Brier score (0 indicates perfect overall performance and 0.25 indicates a noninformative model); C-statistic and 95% CI; Hosmer-Lemeshow goodness-of-fit test and calibration plots; and sensitivity, specificity, and positive and negative predictive values.
RESULTS: The 1879 patients in the study had a median (IQR) age of 79 (74-84) years and 835 were women (44.4%). The median (IQR) number of chronic diseases was 11 (8-16). Within 1 year, 375 participants (20.0%) died. Brier scores ranged from 0.16 (Gagné Index) to 0.24 (Burden of Illness Score for Elderly Persons). C-statistic values ranged from 0.62 (95% CI, 0.59-0.65) for Charlson Comorbidity Index to 0.69 (95% CI, 0.66-0.72) for the Walter Index. Calibration was good for the Gagné Index and moderate for other mortality risk scores.
CONCLUSIONS AND RELEVANCE: Results of this prognostic study suggest that all 6 of the 1-year mortality risk scores examined had moderate prognostic performance, discriminatory power, and calibration in a large cohort of hospitalized older adults with multimorbidity. Overall, none of these mortality risk scores outperformed the others, and thus none could be recommended for use in daily clinical practice.
参考来源
- Schneider C, Aubert CE, Del Giovane C, et al. Comparison of 6 Mortality Risk Scores for Prediction of 1-Year Mortality Risk in Older Adults With Multimorbidity. JAMA Netw Open. 2022. PMID: 35895059. doi:10.1001/jamanetworkopen.2022.23911
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。